Matinas BioPharma Holdings, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that Jerome D. Jabbour , Co-founder and President will present at NobleCon13, the Noble Capital Markets’ Thirteenth Annual Investor Conference, on January 30, 2017 at 1:00 p.m. ET in Boca Raton, FL. During his presentation, Mr. Jabbour will provide a corporate and clinical update, and will discuss Matinas’ Phase 2 clinical program of its lead antifungal product candidate, MAT2203 , an orally administered, lipid-crystal nano-particle formulation of broad spectrum fungicidal agent amphotericin B, and its plans to advance into a pivotal, registration program.
Category: Medicine
What Makes The IPhone Special
When you want to uncover your iPhone, there are a few methods to move about doing so. If you’ve been faithful to your contract, you could be able to do so by way of your carrier network or perhaps by way of a network-authorized service.
Samsung Pills
Consumer Intelligence Research Companions released analysis associated with the results of its study on cellular phone operating techniques and brands for the work schedule quarter that ended Summer 30, 2015. Overall, with ANDROID OS and Microsoft Exchange Server hosting from a credit card applicatoin service company, companies can add the Android Program to their worker marketing communications options confidently.
Public-private ping pong and conflict of interest concerns
Every week, we’re on the lookout for thought-provoking and off-the-radar bits of health news. Here’s a selection of stories from this week’s health newsletter, Second Opinion.
Why are Americans wary of advances in biotechnology?
We are truly living in a remarkable era of biotechnological progress. Emerging nanotechnologies and immunotherapies offer the possibility of the targeted destruction of cancerous cells.
The proliferative and chronotropic effects of Brillantaisia nitens…
Brillantaisia nitens Lindau leaves are commonly used in traditional medicine in Africa for the treatment of many disorders including heart diseases and malaria. In this study, we therefore evaluated the effect of the methylene chloride/methanol leaf extract of Brillantaisia nitens on the proliferation of mouse pluripotent stem cells and their cardiomyocyte derivatives.
UC San Diego researchers receive CIRM grants to advance studies on Zika virus and cancer
The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine has approved a pair of $2 million awards to University of California San Diego School of Medicine researchers to advance studies of new treatments for Zika virus infections and the use of stem cell-derived natural killer cells to target ovarian cancer and other malignancies. The Zika virus is linked to increased birth defects, most notably microcephaly – newborns with smaller than expected heads and abnormal brain development.
Soft Robot Helps the Heart Beat
Harvard University and Boston Children’s Hospital researchers have developed a customizable soft robot that fits around a heart and helps it beat, potentially opening new treatment options for people suffering from heart failure. The soft robotic sleeve twists and compresses in synch with a beating heart, augmenting cardiovascular functions weakened by heart failure.
p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA
467 Zhongshan Road, Shahekou District, Dalian, Liaoning 116000, China. E-mail: dlzhaozw@163.com Aberrant p62 overexpression has been implicated in breast cancer development.
Proclaim DRG Dorsal Root Ganglion Neurostimulator for Chronic Pain Released in Europe
St. Jude Medical , now a part of Abbott , is making available in Europe its Proclaim DRG Neurostimulation System. The implant features 4-ports and 16-channels to help control chronic neuropathic pain by electrically stimulating the dorsal root ganglion , a body of neurons responsible for managing pain signals moving up the spine.
Athersys Subsidiary and Leading Animal Health Company Enter Into…
Athersys, Inc. announced today that through its Belgian subsidiary, ReGenesys BVBA , it has entered into an agreement with a global leader in the animal health business segment to evaluate the cell therapy technology for application in a non-disclosed animal health area. Under the terms of the agreement, ReGenesys will receive an initial payment in exchange for an exclusive period to evaluate the cell therapy technology with an option to negotiate for a license for the development and commercialization of the technology for this area.
Greenwood, SC
Full time position at busy medical practice managing front desk. M-F 8:30-5:30. Previous medical billing experience preferred.
Mount Sinai department builds 3D models in short order
Surgery sometimes can yield surprises for physicians as they operate on the human body. Now, three-dimensional modeling can take away some of that guesswork.
CPE.H – Capital Pro Egaux Inc.
Capital Pro-Egaux licenses patents to nSequence et al. 2017-01-10 09:21 MT – News Release Mr. Pierre Desormeau reports CAPITAL PRO-EGAUX INC. ANNOUNCES THE CONCLUSION OF A LICENSE AGREEMENT WITH NSEQUENCE CENTER FOR ADVANCED DENTISTRY AND NATIONAL DENTEX CORPORATION Capital Pro-Egaux Inc.’s wholly owned subsidiary, Technique d’usinage Sinlab Inc., has entered into a patent licence agreement with nSequence Center for Advanced Dentistry and National Dentex Corp. As part of the agreement, Sinlab granted licensees a non-exclusive worldwide licence to make, use, sell and offer to sell inventions covered by its patents, including patents relating to its Technobar and Technoguide technologies, under terms undisclosed for confidentiality reasons.
This super bowel ad will show you surgery happening live – CNET
British charity Cancer Research UK is preparing to show a live TV advert of a colonoscopy procedure to highlight the simple ways you can look out for and prevent cancer. Doctor Sunil Dolwani will talk viewers through the procedure, broadcast live in a commercial break, as the surgical team removes polyps from the bowels of patient Philip McSparron at Cardiff and Vale University hospital.
Brokerages Set $6.00 Target Price for Athersys, Inc.
Shares of Athersys, Inc. have earned a consensus broker rating score of 1.00 from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.
3 Bold Bets on the Future of Healthcare
Healthcare is changing rapidly. Which companies will emerge as the huge winners with these major changes? We asked three of our healthcare contributors to weigh in on the subject.
Genome Engineering Staff Researcher – Hsu Laboratory
Research in the Hsu lab takes place at the intersection of bioengineering, genomics, and neuroscience to develop novel genome engineering technologies and uncover biological mechanisms behind neurodegenerative diseases and cancer. The Hsu Lab is recruiting to develop and apply novel technologies for precise and efficient manipulation of genetic and cell states.
Credentials of doctor connected to cosmetic surgery deaths questioned
But there is nothing normal about two women dying this year following cosmetic procedures at Dodds’ office in Kennesaw, GA. “I saw the day of the funeral them roll the coffin out and I saw Serge, my son, and I saw two other guys pick up the coffin and I’m calling and I’m calling and I’m calling and no response,” Erica Beaubrun’s mother, Elsie Albert, said.
Scientists reprogram embryonic stem cells to expand their potential
Researchers from UC Berkeley have found a way to reprogram mouse embryonic stem cells so that they exhibit developmental characteristics resembling those of fertilized eggs, or zygotes. While typical embryonic stem cells are unable to make tissues like the placenta, which allow the embryo to communicate with the mother, blocking a microRNA unleashes the potential to make these extra-embryonic tissues .
Johns Hopkins researchers helping in search for elusive cancer causing genes
A group of scientists at Johns Hopkins University is studying various bioinformatics methods to discover the ones that help identify the genetic mutations that encourage tumor cells to thrive in an effort to develop drugs to fight the cancer. A group of scientists at Johns Hopkins University is studying various bioinformatics methods to discover the ones that help identify the genetic mutations that encourage tumor cells to thrive in an effort to develop drugs to fight the cancer.
Teaching Computers to Recognize Sick Guts: Machine-Learning and the Microbiome
A new proof-of-concept study by researchers from the University of California San Diego succeeded in training computers to “learn” what a healthy versus an unhealthy gut microbiome looks like based on its genetic makeup. Since this can be done by genetically sequencing fecal samples, the research suggests there is great promise for new diagnostic tools that are, unlike blood draws, non-invasive.
Five ways to make your child a creative genius
Congratulations! Your child is already a creative genius by virtue of being human. Humans are far more creative than any other species.
Diabetes: Stimulating bone stem cells may improve fracture repair
Researchers have discovered a protein that stimulates bone stem cells in mice with diabetes so that the animals heal better after a fracture. They suggest that this could lead to a new treatment to improve bone repair in people with diabetes.
Biden’s Cancer Moonshot Draws on Aussie Nobel-Winning Expertise
U.S. Vice President Joe Biden arrived in Melbourne last July with his granddaughters in tow. Bypassing sporting stadiums and race-car tracks, Biden’s first official stop in the world’s sporting capital was to open a A$1 billion cancer center.
FDA Advice on Hacking Threat to Cardiac Device
The U.S. Food and Drug Administration has issued new advice about how to safeguard implantable cardiac devices against hackers. A wireless transmitter used to transmit data from cardiac devices to medical providers, the Merlin@home Transmitter made by St. Jude Medical was found to be vulnerable to online hacking, the FDA said.
US warns of unusual cybersecurity flaw in heart devices
This Wednesday, July 22, 2015, file photo shows St. Jude Medical corporate headquarters, in Little Canada, Minn., just north of St. Paul. The Homeland Security Department is warning the public about an unusual cybersecurity flaw for one manufacturer’s implantable heart devices that could allow hackers to remotely take control of a person’s defibrillator or pacemaker.
US warns of unusual cybersecurity flaw in heart devices
The Homeland Security Department warned Tuesday about an unusual cybersecurity flaw for one manufacturer’s implantable heart devices that it said could allow hackers to remotely take control of a person’s defibrillator or pacemaker. Information on the security flaw, identified by researchers at MedSec Holdings in reports months ago, was only formally made public after the manufacturer, St. Jude Medical, made a software repair available Monday.
FDA: Cardiac device info vulnerable to hackers
If you used an Optimum login , click the Connect Account button to use your Optimum login info to manage your Newsday subscription account. If you used a Newsday login , it looks like it’s not connected to an active subscriber account.
Unique Nanoparticle Properties Confound Fluorescent Based Assays…
Dreher, K. AND W. Polk. Unique Nanoparticle Properties Confound Fluorescent Based Assays Widely Employed in Their In Vitro Toxicity Testing and Ranking.
Are you ready for January 22?
She’ll back in the Sault on July 1 to preside over our 150th anniversary of Canada celebrations. In Roberta Bondar Park, of course! January 22 will be the 25th anniversary of Dr. Roberta Bondar’s launch from Earth aboard the Space Shuttle Discovery, becoming the second Canadian astronaut in space, the world’s first neurologist in space and Canada’s first women in space.
Secretive Biotech Unicorn Moderna Unveils Pipeline, Financials
Moderna Therapeutics Inc., one of the best-funded private biotechnology companies in the U.S., unveiled its long-secret research and development pipeline on Monday, including experimental vaccines, cancer treatments and a cardiovascular therapy. The Cambridge, Massachusetts-based startup has about $1.3 billion in cash on hand from investors, pharmaceutical partners and government grants, according to a presentation Monday at the J.P.Morgan Chase & Co.
St. Jude says it’s working to protect pacemakers from hackers :0
Nearly five months after ending up in the crosshairs of a short seller, St. Jude Medical said Monday it’s upgrading its cybersecurity to enhance the safety of its implantable heart devices. The updates come after the Food and Drug Administration found that St. Jude’s heart devices have “vulnerabilities” that could allow hackers to break into pacemakers, resulting in battery depletion or “inappropriate pacing or shocks.”
Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook and Financial Guidance
Amicus Therapeutics , a global biotechnology company at the forefront of therapies for rare and orphan diseases, today provided its full-year 2017 strategic outlook and financial guidance. “In 2016 we made significant progress in our transformation to a global commercial-stage biotech company while we continued to advance and expand our tremendous pipeline of first- and/or best-in-class medicines for people living with devastating rare diseases,” stated John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. “We begin 2017 in an excellent position to develop and deliver great medicines for patients and to create significant shareholder value.
Biotechs are paying a price for their high drug costs
The biotech industry hit a speed bump in 2016 after logging accelerating growth for years. US drug approvals fell to just 22 – from 45 in 2015 – a six-year low.
Here’s Why Alnylam Pharmaceuticals Plunged 59.8% in 2016
A major clinical setback removed a potential blockbuster drug from Alnylam’s pipeline and led to a collapse in the company’s share price. . Shares of the RNAi-focused biotech utterly collapsed, falling by nearly 60% during the year, according to data from S&P Global Market Intelligence .
Here’s Why Alnylam Pharmaceuticals Plunged 59.8% in 2016
A major clinical setback removed a potential blockbuster drug from Alnylam’s pipeline and led to a collapse in the company’s share price. . Shares of the RNAi-focused biotech utterly collapsed, falling by nearly 60% during the year, according to data from S&P Global Market Intelligence .
Carlyle Said to Explore Sale of Vitamin Maker Nature’s Bounty
Carlyle Group LP is exploring a sale of nutritional-supplements maker Nature’s Bounty Co., whose brands include “MET-Rx” and “Pure Protein,” people with knowledge of the matter said. The private equity firm has held talks with potential advisers about selling the U.S. company, formerly known as NBTY Inc., according to the people.
GenomeCAT: a versatile tool for the analysis and integrative…
The analysis of DNA copy number variants has increasing impact in the field of genetic diagnostics and research. However, the interpretation of CNV data derived from high resolution array CGH or NGS platforms is complicated by the considerable variability of the human genome.
GenomeCAT: a versatile tool for the analysis and integrative…
The analysis of DNA copy number variants has increasing impact in the field of genetic diagnostics and research. However, the interpretation of CNV data derived from high resolution array CGH or NGS platforms is complicated by the considerable variability of the human genome.